Biological treatment of psoriasis shows a good efficacy in clinical trials. Since most analyses have focused on short-term outcomes of single biological agents, little has been known about long-term outcomes in clinical practice, where switching between biological agents is common. A study that followed 583 individuals for up to 10 years shows a satisfactory long-term effectiveness of biologic treatments.
A new study tested the efficacy of tildrakizumab, an antibody that targets only a very specific immune system pathway. More than 60 percent of all patients who received the active medication showed improvement, compared to less than 10 percent of patients who received placebos.
There were notably more remissions with Secukinumab and ixekizumab than under the comparator therapies for psoriasis. In future, the analysis of symptoms should not be limited to improvements at one time point.
A newly developed tissue scanner allows looking under the skin of psoriasis patients. This provides clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure.
Patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced a significant reduction in symptoms, including joint tenderness and swelling, have reported promising results when they were given a new drug.
Superficially, psoriasis and atopic dermatitis may appear similar but their commonalities are only skin deep. Atopic dermatitis, also known as eczema, is primarily driven by an allergic reaction, while psoriasis is considered an autoimmune disease. Nevertheless, researchers were able to pinpoint a common driver of skin inflammation in both diseases.